Headlines about InVitae Corp (NASDAQ:NVTA) have been trending somewhat positive on Friday, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. InVitae Corp earned a news impact score of 0.12 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 47.0472066153793 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news stories that may have effected Accern’s analysis:

A number of analysts recently weighed in on the stock. BidaskClub cut shares of InVitae Corp from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Zacks Investment Research cut shares of InVitae Corp from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. J P Morgan Chase & Co restated an “overweight” rating and set a $15.00 target price (up from $14.00) on shares of InVitae Corp in a report on Wednesday, August 9th. Finally, ValuEngine cut shares of InVitae Corp from a “sell” rating to a “strong sell” rating in a report on Tuesday, May 23rd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $12.94.

InVitae Corp (NASDAQ NVTA) traded down 5.77% during trading on Friday, reaching $9.80. 245,339 shares of the company were exchanged. The firm has a 50-day moving average of $9.61 and a 200-day moving average of $9.87. InVitae Corp has a 52-week low of $5.76 and a 52-week high of $11.88. The firm’s market cap is $426.73 million.

InVitae Corp (NASDAQ:NVTA) last announced its quarterly earnings data on Monday, August 7th. The medical research company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.02. The company had revenue of $14.34 million for the quarter, compared to analyst estimates of $13.31 million. InVitae Corp had a negative return on equity of 153.27% and a negative net margin of 199.20%. The business’s quarterly revenue was up 157.0% compared to the same quarter last year. During the same period last year, the business earned ($0.77) EPS. On average, equities analysts forecast that InVitae Corp will post ($2.35) EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/25/invitae-corp-nvta-given-daily-coverage-optimism-score-of-0-12.html.

About InVitae Corp

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Insider Buying and Selling by Quarter for InVitae Corp (NASDAQ:NVTA)

Receive News & Stock Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related stocks with our FREE daily email newsletter.